To further evaluate the relevance of the LINC00589-miR-100-DLG5 and LINC00589-miR-452-PRDM16-MUC4 networks in clinical samples, we evaluated expression levels in HER2-positive breast cancer patients. This evidence concerns the gene PRDM16 and breast cancer.